GE HealthCare Technologies Inc. (GEHC)
Health Care · Health Care Equipment · US stock · S&P 500 component
$71.42
▲ +2.41 (3.49%)
Fair valueUndervalued
$84 +17.7% to fair value
$42fair band $72–$102$126
Day's range
$69.31 – $71.70
52-week range
$58.75 – $89.77
About GE HealthCare Technologies Inc.
Hospitals and clinics use medical imaging machines, patient monitoring equipment and diagnostic agents from GE HealthCare. Its products include MRI, CT, X-ray and ultrasound systems, along with contrast agents, radiopharmaceuticals, and digital software and services that help clinicians interpret images and manage care. The company was separated from General Electric and is organised into imaging, advanced visualisation, patient care and pharmaceutical diagnostics businesses.
Revenue comes from equipment, from service contracts that support installed machines, and from recurring supplies such as contrast agents. Sales were $21.0 billion over the last twelve months, rising 4.0% a year over the last three years. The operating margin is 12.6%, and the business earns a profit of 11% on the capital invested in it. Net debt is 3.1 times EBITDA. It pays a dividend with a yield of 0.2%. On the site's X-Ray Score it receives 49 out of 100.
Price chart
52-wk range $58.75 – $89.77Volume 3,131,579Daily, split-adjusted
Vitals
Market cap$32.6B
52-week range$58.75 – $89.77
Volume (last day)3,131,579
P/E (TTM)17.1
EBIT / EV yield6.5%
Free-cash-flow yield–
Dividend yield0.2%
Revenue (TTM)$21.0B
Net income (TTM)$1.9B
Operating margin12.6%
Return on capital10.7%
Debt incl. leases$10.5B
Cash & securities$2.3B
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies that hold large long-term investments). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$84middle half of models $76 – $90
Undervalued
+17.7% to fair value
Average of the 13 valuation models that pass our checks: multiples, discounted cash flow, dividend discount and earnings power value. A model more than 100% above or 60% below the price is left out as unrealistic. Model uncertainty is Medium, based on how far apart the models are. Undervalued or Overvalued means the gap to fair value is more than 17.5%.
Price $71
Undervalued < $72Fair $72 – $102Overvalued > $102
P/E multiple
$72
P/B multiple
$90
P/S multiple
$122
EV/EBITDA multiple
$79
EV/EBIT multiple
$84
EV/revenue multiple
$106
10-year DCF, EBITDA exit
$76
5-year DCF, EBITDA exit
$78
10-year DCF, revenue exit
$79
5-year DCF, revenue exit
$82
10-year DCF, growth exit
$66
5-year DCF, growth exit
$65
Dividend discount, stable · not used
$5
Dividend discount, multi-stage · not used
$8
Earnings power value
$93
Growth the price implies
9.7%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.13%, equity risk premium 4.30% (Damodaran). How it works.
What this means
Weak business, but the price is low
Our models put fair value above today's price, but models can be wrong, so check the business first. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Strong: 70 to 100Fair: 50 to 69Weak: under 50No score: not enough data
Valuation
Strong
81/100
Cheap against its sector on earnings and cash flow.
See the numbers →
EBIT / EV yield6.5%
Fair value vs price1.2×
Growth
Weak
38/100
Growing slower than most of its sector.
See the numbers →
Revenue growth (3y)4.0%
EPS growth (3y)2.5%
Growth consistency90%
Profitability
Weak
46/100
Earns lower returns on its capital than most peers.
See the numbers →
Return on invested capital10.7%
Operating margin12.6%
Gross profitability22.1%
Financial health
Weak
38/100
Balance sheet is more stretched than most peers.
See the numbers →
Piotroski F-Score5 / 9
Net debt / EBITDA3.1×
Interest coverNo interest cost
Dividends
Weak
17/100
Dividend is modest or less certain than peers.
See the numbers →
Dividend yield0.2%
Quarterly results: last 6 quarters
+2.2%
Dec '24
+2.7%
Mar '25
+3.5%
Jun '25
+5.8%
Sep '25
+7.1%
Dec '25
+7.4%
Mar '26
Revenue against the same quarter a year earlier. Latest quarter revenue $5.1B, diluted EPS $0.85.
Compare with peers
DXCM Dexcom Inc78 PODD Insulet Corp72 RMD Resmed Inc70 BSX Boston Scientific Corp67Other Health Care Equipment companies by X-Ray Score.
SWOT analysis: GE HealthCare Technologies Inc.
Strengthsinside the company
- Operating profit covers interest 50x, so debt costs are a small drag.
Weaknessesinside the company
- Altman Z-score of 1.7 is in the zone linked with financial distress in past studies.
Opportunitiesvaluation and setting
- Trades at 17.1x earnings, 45% below the 31.2x median of industry peers.
- The price is 18% below our fair value estimate, with the gap larger than the margin we allow for error.
Threatsvaluation and setting
- No specific threat is flagged by our checks; general market and interest-rate risk still applies.
Written by fixed rules from the figures on this page and the peer table below: filings, our fair value, the sector climate and the price trend. It summarises the data, it is not a forecast or advice.
Compare GEHC with peers and sector
Medians of 15 Health Care Equipment peers and of 59 Health Care stocks in our universe.
Largest peers (X-Ray Score): ABT 41, ISRG 62, MDT 57, SYK 56, BSX 67, BDX 47.
| Metric | GEHC | Peers | Sector |
|---|---|---|---|
| X-Ray Score (out of 100) | 49 | 57 | 49 |
| Valuation | 81 | 57 | 52 |
| Growth | 38 | 74 | 48 |
| Profitability | 46 | 55 | 51 |
| Financial health | 38 | 64 | 48 |
| Dividends | 17 | 57 | 52 |
Sector leaders: highest X-Ray Score in Health Care
GEHC ranks #31 of 60 in Health Care and #12 of 16 in Health Care Equipment by X-Ray Score. A higher score is stronger on our five pillars; it is a ranking of facts, not a forecast.
Green means better than the peer median, red worse (only where a higher or lower figure is clearly better). A dash means too few companies report the figure. P/E, EV/EBITDA and price changes are not graded: a different level is not good or bad by itself.
Factor ratings for GEHC
Each factor is rated by where GEHC stands among the 60 Health Care stocks in our universe.
Rating against the sector
Goodthe top third of these stocks
Averagethe middle third of these stocks
Badthe bottom third of these stocks
"Beats" is the share of those stocks it is ahead of.
Against its own history
The last columns set today's figure against the company's own median of its last five financial years:
▲ Betterbetter than its usual level
▼ Worseworse than its usual level
≈ In linewithin its usual range
For valuation factors Good means cheaper than most of the sector and Better means cheaper than usual for this company, which is not the same as a bargain.
In total: 3 Good · 8 Average · 5 Bad of 16
Growth: 0 · 2 · 1
Profitability: 0 · 4 · 1
Financial strength: 1 · 0 · 3
Valuation: 2 · 2 · 0
| Factor | GEHC | Rating | Sector median | Own 5-year median | Against own history |
|---|---|---|---|---|---|
| Growth | |||||
| Revenue growth, 3 years a year | +4.0% | Average beats 41% | +5.5% | – | – |
| Revenue growth, last year | +4.8% | Bad beats 33% | +7.1% | +4.6% | ≈ In line |
| EPS growth, 3 years a year | +2.5% | Average beats 40% | +5.0% | – | – |
| Profitability | |||||
| Gross margin | 39.1% | Bad beats 25% | 65.0% | 40.5% | ≈ In line |
| Operating margin | 12.6% | Average beats 38% | 16.4% | 13.4% | ≈ In line |
| Net margin | 9.1% | Average beats 42% | 11.1% | 10.1% | ▼ Worse |
| Return on invested capital | 10.7% | Average beats 44% | 12.2% | – | – |
| Return on equity | 17.9% | Average beats 63% | 13.7% | 20.5% | ▼ Worse |
| Financial strength | |||||
| Net debt / EBITDA | 3.1x | Bad beats 30% | 2.0x | 2.8x | ▼ Worse |
| Interest cover | 50.0x | Good beats 82% | 9.4x | – | – |
| Current ratio | 1.22 | Bad beats 29% | 1.52 | 1.10 | ▲ Better |
| Piotroski F-score | 5 / 9 | Bad beats 25% | 6 / 9 | – | – |
| Valuation | |||||
| P/E ratio | 17.1x | Good beats 84% | 28.2x | 18.0x | ≈ In line |
| Price / book | 3.1x | Average beats 65% | 3.7x | 3.9x | ▲ Better |
| Price / sales | 1.6x | Good beats 74% | 3.7x | 1.8x | ≈ In line |
| EV / EBITDA | 15.5x | Average beats 61% | 17.6x | 16.2x | ≈ In line |
These ratings compare companies with each other and describe the past; they are not a forecast, a recommendation or part of the X-Ray Score. A factor is left out when its data is missing or meaningless (for example a P/E on negative earnings). A dash in the history columns means fewer than three usable years.
Fundamentals checklist
● 3 Good · ● 5 Average · ● 5 BadCash quality
Risk models
Altman Z''Bad
Piotroski F-ScoreBad
Growth
EPS growth (3y)Average
Revenue growth (3y)Average
Growth consistencyAverage
Balance sheet
Current ratioBad
Net debt / EBITDABad
Interest coverGood
Valuation
Fair value vs priceGood
EBIT / EV yieldGood
Profitability
Return on invested capitalAverage
Operating marginAverage
Gross profitabilityBad
Each check is graded against the company's sector, not a fixed number. Checklist score 47/100.
Financials
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $17.6B | $18.3B | $19.6B | $19.7B | $20.6B |
| Operating income | $2.8B | $2.5B | $2.4B | $2.6B | $2.8B |
| Net income | $2.2B | $1.9B | $1.6B | $2.0B | $2.1B |
| Operating cash flow | – | – | – | – | – |
| Operating margin | 15.9% | 13.8% | 12.5% | 13.3% | 13.4% |
| Free cash flow | – | – | – | – | – |
| Diluted EPS | $4.95 | $4.22 | $3.03 | $4.34 | $4.55 |
Fiscal years, from SEC filings.
Technical summary
Daily
Strongly bullish
12 bullish · 1 neutral · 3 bearish
Weekly
Neutral
6 bullish · 1 neutral · 5 bearish
Monthly
Bearish
2 bullish · 1 neutral · 4 bearish
Moving averages (daily)
| SMA 10 | 69.11 | Bullish |
| EMA 10 | 69.09 | Bullish |
| SMA 20 | 67.20 | Bullish |
| EMA 20 | 68.06 | Bullish |
| SMA 50 | 68.41 | Bullish |
| EMA 50 | 67.61 | Bullish |
| SMA 100 | 66.83 | Bullish |
| EMA 100 | 67.86 | Bullish |
| SMA 200 | 70.15 | Bullish |
| EMA 200 | 69.55 | Bullish |
Oscillators (daily)
| RSI (14) | 64.48 | Neutral |
| MACD (12, 26) | 0.95 | Bullish |
| Momentum (12) | 10.27 | Bullish |
| Stochastic %K (14) | 96.66 | Bearish |
| Williams %R (14) | -3.34 | Bearish |
| CCI (20) | 119.5 | Bearish |
Pivot points (classic, last session)
S3 67.53 | S2 68.42 | S1 69.92 | Pivot 70.81 | R1 72.31 | R2 73.20 | R3 74.70 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
0.18 USD
Yield on today's price
0.25%
Frequency
Quarterly
Next ex-dividend date
Not announced
| Ex-dividend date | Amount per share |
|---|---|
| 0.0400 | |
| 0.0350 | |
| 0.0350 | |
| 0.0350 | |
| 0.0350 | |
| 0.0350 | |
| 0.0350 | |
| 0.0350 | |
| 0.0300 | |
| 0.0300 | |
| 0.0300 | |
| 0.0300 |
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
ETFs that hold GEHC
| ETF | Share of the fund |
|---|---|
| IHI iShares U.S. Medical Devices | 4.51% |
| MOAT VanEck Morningstar Wide Moat | 2.21% |
| QQQE Direxion NASDAQ-100 Equal Weighted Ind... | 1.11% |
| JAVA JPMorgan Active Value | 1.08% |
| IYH iShares U.S. Healthcare | 0.51% |
| XLV Health Care Select Sector SPDR | 0.51% |
| VOE Vanguard Mid-Cap Value | 0.50% |
| VHT Vanguard Health Care | 0.45% |
The eight funds with the largest weight in GEHC among the ETFs we cover, from each fund's latest SEC Form N-PORT (quarter-end positions, so they can be months old). All ETFs.
GEHC SEC filings
8-KSEC EDGAR
Director or officer change; Regulation FD disclosure
8-KSEC EDGAR
Director or officer change
8-KSEC EDGAR
Regulation FD disclosure
10-QSEC EDGAR
Quarterly report
8-KSEC EDGAR
Results of operations
8-KSEC EDGAR
Results of operations; Director or officer change
8-KSEC EDGAR
Shareholder vote results; Other events
10-QSEC EDGAR
Quarterly report
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.